It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Prevention of infectious diseases is based on host protection, especially using vaccines. Several factors have been linked to the acceptance of vaccines in the population. Chile achieved high COVID-19 vaccination coverage early in the pandemic. The study aimed to determine the prevalence of antigens and antibodies, vaccination status, geographical distribution, and factors related to vaccine acceptability.
Methods
In two Chilean cities, the fourth round of a population-based seroprevalence cross-sectional survey was conducted in May 2024. 654 participants aged seven or older were recruited. After signing consent, participants were interviewed, blood samples were taken to identify antibodies against SARS-CoV-2 using ELISA, and antigens were assessed through a nasal swab rapid test. Territorial analysis of the vaccine dose distribution was carried out.
Results
All participants tested negative for antigens and positive for antibodies against SARS-CoV-2, with an overall vaccination uptake rate of 98,5%. However, their vaccination status was heterogeneous. Territorial distribution showed a slight geographical clustering of vaccine doses in both cities. 52.7% had the basic scheme and/or boosters, 32.1% had the bivalent vaccine, and 13.7% had anti-Omicron. Self-report identification with a risk group was not associated with vaccine adherence. City, age, education, and comorbidities were associated with perceived and actual risk discrepancies.
Conclusions
Overall, vaccine acceptance is high. However, the acceptance of the last two doses was below expectations and showed heterogeneous geographical distribution. Adulthood is the most important predictor of vaccine uptake. Participants underestimated their level of risk. Risk communication must be improved, especially for risk groups, to help them perceive themselves as beneficiaries of vaccination. Efforts should be made to disseminate information on vaccine safety and counter misinformation to increase knowledge about vaccines.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer